Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow 2.5mg and 5mg differ in practice, and what that means for your treatment
You're on 2.5mg and wondering if it's actually doing anything
This is a question our prescribers hear most weeks. You've used your first pen, the nausea was manageable, and the scales haven't moved much. That's not a failure, it's the design. The 2.5mg starting dose exists purely for tolerability. Tirzepatide activates both GIP and GLP-1 receptors, which slows gastric emptying and reduces appetite, and those effects can cause nausea, reflux or loose stools if the dose jumps too high too quickly. Starting low gives your gut time to adapt.
So if you feel like 2.5mg isn't doing much, you're not wrong. The 2.5mg dose page covers what the first four weeks typically involve. Most people move to 5mg after that first pen, provided their prescriber is satisfied with how the starter dose was tolerated. The clinical question at that point isn't whether you've lost enough weight, it's whether your system is ready for a meaningful therapeutic dose.
It's worth keeping a rough record of any side effects during those first four weeks. That information is exactly what a prescriber needs when reviewing your case before the next step.
What changes at 5mg, the evidence and the experience
Five milligrams is the first dose where most people begin to notice real appetite suppression. The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed thousands of adults with obesity over 72 weeks; at the maximum dose of 15mg, participants achieved around 20–21% average body-weight reduction. The trajectory to that outcome starts at 5mg. Participants didn't arrive at the maintenance dose instantly, the stepped titration schedule is a core part of how the medicine works safely.
At 5mg, appetite changes tend to become more noticeable: smaller portions feel satisfying, and the drive to eat between meals often reduces. GI side effects can temporarily increase after the step up, then usually settle within one to two weeks. If you're comparing what 5mg versus higher doses deliver over time, the 5mg vs 7.5mg comparison picks up from here.
The NHS tirzepatide medicines page outlines common side effects at each stage, worth reading before any dose change.
Side by side: 2.5mg vs 5mg at a glance
The table below summarises the key practical differences, and if you want a deeper look at how these two doses compare clinically, our guide to Mounjaro 2.5 vs 5 walks through what sets them apart. Numbers from the SURMOUNT programme are cited above; the clinical steps reflect the licensed UK dosing schedule from the Mounjaro SmPC.
| Feature | 2.5mg | 5mg |
|---|---|---|
| Primary purpose | Tolerability and adjustment | First therapeutic dose |
| Duration (typical) | 4 weeks (first pen) | 4 weeks minimum, or longer if needed |
| Appetite suppression | Mild to minimal for most | More noticeable for most people |
| GI side effects | Often mild; may increase on step-up to 5mg | Can spike briefly after the increase, then ease |
| Weight loss contribution | Limited; tolerability phase | Loss typically begins to accelerate |
| Prescription required | Yes (clinical assessment required | Yes) prescriber review required before step-up |
Neither dose is a shortcut. Both require clinical oversight, and the decision to move from one to the other sits with a prescriber who has reviewed your case. If weight loss stalls after reaching 5mg, plateauing on 5mg is worth reading before drawing conclusions.
The clinical decision that sits between these two doses
Moving from 2.5mg to 5mg isn't automatic. A prescriber reviews your response to the starter dose (tolerability, any side effects, and your current weight) before approving the next pen, and our page on moving from Mounjaro 2.5mg to 5mg explains exactly what that review involves. At nume, that review happens before every repeat, carried out by a named GPhC-registered Independent Prescriber. No repeat is issued without it.
This matters more than it might sound. Dose increases that happen without clinical oversight are one of the patterns seen with counterfeit pens and unregulated sellers, the MHRA has warned publicly about fake tirzepatide pens circulating in the UK, some produced without any quality controls. Always verify any online pharmacy on the GPhC register before placing an order. You can verify nume at registration number 9012878.
Which dose is right for you (and the right pace to move through them) is a clinical decision our prescribers work through with you individually. For a broader picture of how Mounjaro is structured as a treatment, the Mounjaro treatment overview covers the full licensed schedule and what private access involves. Ready to get started? Speak to our prescribers through a free consultation today.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.